Healthcare provider profile · identity verified

George Thottakara Mathai, MD

Allopathic & Osteopathic Physicians|Internal Medicine · NEW JOHNSONVILLE, TN · NPI 1316098858

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show George Thottakara Mathai, MD received $62.84 in general payments during 2025 across 4 reported records.

AstraZeneca Pharmaceuticals LP accounted for 43.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Shingrix by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Abrysvo by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$62.84

4 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$27.12	43.2%	2	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$18.59	29.6%	1	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$17.13	27.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$62.84	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
TRELEGY ELLIPTA Normalized: trelegy ellipta	Drug	GlaxoSmithKline, LLC.	$18.59	1	2025
Source payment records 2025-10-15 · GlaxoSmithKline, LLC. · $18.59 · Open Payments source
NURTEC ODT Normalized: nurtec odt	Drug	PFIZER INC.	$17.13	1	2025
Source payment records 2025-06-16 · PFIZER INC. · $17.13 · Open Payments source
ZAVZPRET Normalized: zavzpret	Drug	PFIZER INC.	$17.13	1	2025
Source payment records 2025-06-16 · PFIZER INC. · $17.13 · Open Payments source
BREZTRI Normalized: breztri	Drug	AstraZeneca Pharmaceuticals LP	$13.65	1	2025
Source payment records 2025-02-03 · AstraZeneca Pharmaceuticals LP · $13.65 · Open Payments source
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$13.47	1	2025
Source payment records 2025-11-10 · AstraZeneca Pharmaceuticals LP · $13.47 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
TRELEGY ELLIPTA trelegy ellipta	2025	Trelegy Ellipta	2024	58	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	46	14
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	SHINGRIX open payments reported associated product	CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452	Shingrix · 2024 Exact normalized brand match · 1 Part D row	50	41
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	58	12
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ABRYSVO open payments reported associated product	CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147	Abrysvo · 2024 Exact normalized brand match · 1 Part D row	42	42
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	222	43

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	850	164
Furosemide	Furosemide	698	119
Pantoprazole Sodium	Pantoprazole Sodium	557	104
Gabapentin	Gabapentin	526	117
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	513	119
Atorvastatin Calcium	Atorvastatin Calcium	479	126
Lisinopril	Lisinopril	436	91
Amlodipine Besylate	Amlodipine Besylate	434	98
Potassium Chloride	Potassium Chloride	421	71
Escitalopram Oxalate	Escitalopram Oxalate	404	67
Losartan Potassium	Losartan Potassium	383	93
Mirtazapine	Mirtazapine	363	56
Alprazolam	Alprazolam	336	87
Famotidine	Famotidine	331	50
Sertraline Hcl	Sertraline Hcl	319	42
Omeprazole	Omeprazole	318	83
Hydrochlorothiazide	Hydrochlorothiazide	294	71
Simvastatin	Simvastatin	290	47
Trazodone Hcl	Trazodone Hcl	274	57
Metoprolol Succinate	Metoprolol Succinate	270	63
Donepezil Hcl	Donepezil Hcl	269	38
Metoprolol Tartrate	Metoprolol Tartrate	249	66
Tamsulosin Hcl	Tamsulosin Hcl	245	56
Duloxetine Hcl	Duloxetine Hcl	243	57
Eliquis	Apixaban	222	43
Memantine Hcl	Memantine Hcl	200	24
Divalproex Sodium	Divalproex Sodium	196	19
Prednisone	Prednisone	191	114
Lorazepam	Lorazepam	188	49
Allopurinol	Allopurinol	187	39
Rosuvastatin Calcium	Rosuvastatin Calcium	184	42
Metformin Hcl	Metformin Hcl	182	55
Citalopram Hbr	Citalopram Hydrobromide	172	34
Buspirone Hcl	Buspirone Hcl	168	31
Montelukast Sodium	Montelukast Sodium	165	40
Metformin Hcl Er	Metformin Hcl	163	31
Tramadol Hcl	Tramadol Hcl	154	34
Enalapril Maleate	Enalapril Maleate	152	30
Meloxicam	Meloxicam	152	55
Carvedilol	Carvedilol	150	30
Fluoxetine Hcl	Fluoxetine Hcl	143	35
Clopidogrel	Clopidogrel Bisulfate	140	42
Januvia	Sitagliptin Phosphate	132	22
Risperidone	Risperidone	130	suppressed
Fluticasone Propionate	Fluticasone Propionate	129	57
Paroxetine Hcl	Paroxetine Hcl	129	19
Topiramate	Topiramate	117	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	110	24
Azithromycin	Azithromycin	109	96
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	109	25
Clonidine Hcl	Clonidine Hcl	106	21
Albuterol Sulfate Hfa	Albuterol Sulfate	104	47
Esomeprazole Magnesium	Esomeprazole Magnesium	101	23
Clonazepam	Clonazepam	100	16
Meclizine Hcl	Meclizine Hcl	99	19
Nitrofurantoin	Nitrofurantoin Macrocrystal	97	16
Glimepiride	Glimepiride	90	30
Ozempic	Semaglutide	90	15
Oxcarbazepine	Oxcarbazepine	89	suppressed
Hydralazine Hcl	Hydralazine Hcl	88	20
Ciprofloxacin Hcl	Ciprofloxacin Hcl	85	61
Venlafaxine Hcl Er	Venlafaxine Hcl	85	18
Zolpidem Tartrate	Zolpidem Tartrate	84	19
Atenolol	Atenolol	80	11
Lamotrigine	Lamotrigine	80	suppressed
Jardiance	Empagliflozin	79	16
Baclofen	Baclofen	77	15
Tizanidine Hcl	Tizanidine Hcl	77	14
Lantus	Insulin Glargine,hum.Rec.Anlog	74	11
Celecoxib	Celecoxib	73	18
Spironolactone	Spironolactone	73	22
Ondansetron Hcl	Ondansetron Hcl	71	45
Oxycodone Hcl	Oxycodone Hcl	70	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	67	49
Xarelto	Rivaroxaban	66	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	65	14
Carbidopa-Levodopa	Carbidopa/Levodopa	65	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	64	12
Bupropion Hcl Sr	Bupropion Hcl	64	13
Estradiol	Estradiol	64	22
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	64	40
Amoxicillin	Amoxicillin	63	58
Pregabalin	Pregabalin	62	16
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	62	40
Amiodarone Hcl	Amiodarone Hcl	61	15
Diltiazem 24hr Er	Diltiazem Hcl	61	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	60	41
Ropinirole Hcl	Ropinirole Hcl	59	11
Synthroid	Levothyroxine Sodium	58	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	58	12
Triamcinolone Acetonide	Triamcinolone Acetonide	57	28
Clonidine	Clonidine	55	suppressed
Bupropion Xl	Bupropion Hcl	53	16
Latanoprost	Latanoprost	53	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	52	17
Methocarbamol	Methocarbamol	52	21
Phenytoin Sodium Extended	Phenytoin Sodium Extended	52	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	51	suppressed
Nystatin	Nystatin	50	35
Shingrix	Varicella-Zoster Ge/As01b/Pf	50	41
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	49	suppressed
Finasteride	Finasteride	49	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	49	14
Olanzapine	Olanzapine	47	suppressed
Diazepam	Diazepam	46	12
Farxiga	Dapagliflozin Propanediol	46	14
Fluconazole	Fluconazole	46	37
Warfarin Sodium	Warfarin Sodium	46	14
Diltiazem 12hr Er	Diltiazem Hcl	45	suppressed
Propranolol Hcl	Propranolol Hcl	45	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	43	suppressed
Promethazine Hcl	Promethazine Hcl	43	19
Valsartan	Valsartan	43	11
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	42	42
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	14
Fenofibrate	Fenofibrate Nanocrystallized	42	suppressed
Irbesartan	Irbesartan	42	suppressed
Benazepril Hcl	Benazepril Hcl	41	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	13
Sucralfate	Sucralfate	41	13
Trulicity	Dulaglutide	41	suppressed
Diltiazem Hcl	Diltiazem Hcl	40	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	40	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	40	suppressed
Glipizide	Glipizide	39	suppressed
Pravastatin Sodium	Pravastatin Sodium	39	15
Doxycycline Monohydrate	Doxycycline Monohydrate	38	26
Cephalexin	Cephalexin	37	24
Levetiracetam	Levetiracetam	37	suppressed
Novolin R	Insulin Regular, Human	36	suppressed
Nifedipine Er	Nifedipine	35	suppressed
Aripiprazole	Aripiprazole	34	suppressed
Mounjaro	Tirzepatide	34	suppressed
Alendronate Sodium	Alendronate Sodium	33	suppressed
Bumetanide	Bumetanide	33	suppressed
Doxepin Hcl	Doxepin Hcl	33	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	32	16
Lovastatin	Lovastatin	31	suppressed
Naproxen	Naproxen	31	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	30	suppressed
Breo Ellipta	Fluticasone/Vilanterol	28	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Megestrol Acetate	Megestrol Acetate	28	suppressed
Ondansetron Odt	Ondansetron	28	23
Phenobarbital	Phenobarbital	28	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Morphine Sulfate Er	Morphine Sulfate	25	suppressed
Valacyclovir	Valacyclovir Hcl	25	15
Dexamethasone	Dexamethasone	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	24	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	24	12
Belsomra	Suvorexant	23	suppressed
Lidocaine	Lidocaine	23	suppressed
Morphine Sulfate	Morphine Sulfate	23	21
Ranolazine Er	Ranolazine	23	suppressed
Rivastigmine	Rivastigmine	23	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	23	suppressed
Lacosamide	Lacosamide	22	suppressed
Levofloxacin	Levofloxacin	22	17
Metolazone	Metolazone	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	21	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	21	suppressed
Memantine Hcl Er	Memantine Hcl	20	suppressed
Novolin N	Insulin Nph Human Isophane	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Pentoxifylline	Pentoxifylline	20	suppressed
Clindamycin Hcl	Clindamycin Hcl	19	13
Cyproheptadine Hcl	Cyproheptadine Hcl	19	suppressed
Digoxin	Digoxin	19	suppressed
Lidocaine Hcl	Lidocaine Hcl	19	12
Rivastigmine	Rivastigmine Tartrate	19	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Ceftriaxone	Ceftriaxone Sodium	18	11
Linzess	Linaclotide	18	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	17	suppressed
Fenofibrate	Fenofibrate,micronized	17	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	17	suppressed
Prednisolone Acetate	Prednisolone Acetate	17	suppressed
Verapamil Sr	Verapamil Hcl	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Dutasteride	Dutasteride	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	16	suppressed
Novolog	Insulin Aspart	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	15	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Icosapent Ethyl	Icosapent Ethyl	15	suppressed
Nystop	Nystatin	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Glyburide	Glyburide	14	suppressed
Metronidazole	Metronidazole	14	suppressed
Olanzapine Odt	Olanzapine	14	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	14	suppressed
Brilinta	Ticagrelor	13	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	13	suppressed
Loxapine	Loxapine Succinate	13	suppressed
Modafinil	Modafinil	13	suppressed
Primidone	Primidone	13	suppressed
Sotalol	Sotalol Hcl	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Tresiba Flextouch U-200	Insulin Degludec	13	suppressed
Acetazolamide	Acetazolamide	12	suppressed
Galantamine Hbr	Galantamine Hbr	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Imipramine Hcl	Imipramine Hcl	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Perphenazine	Perphenazine	12	suppressed
Phenytoin	Phenytoin	12	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	11	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Lumigan	Bimatoprost	11	suppressed
Multaq	Dronedarone Hcl	11	suppressed
Pen Needle	Pen Needle, Diabetic	11	suppressed
Testosterone Cypionate	Testosterone Cypionate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$62.84 · 4 records	AstraZeneca Pharmaceuticals LP	AIRSUPRA, BREZTRI, NURTEC ODT, TRELEGY ELLIPTA, ZAVZPRET	6	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error